I do agree on the business front, they’re a dumpster fire, but the FDA is looking at efficacy, benefit versus risk, and in those categories they score very high IMO.
I agree that this is a short term trade for now pending some resolution of their cash situation and competent management, but I do think they get approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.